Stock Events

Stock Events

iBio 

0
174
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 17Expected
Q1 2026
Q2 2026
Next
-0.06
-0.06
-0.05
-0.04
Expected EPS
-0.062818
Actual EPS
N/A

Financials

-33,461.39%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
85,195Revenue
-28.51MNet Income

Analyst Ratings

$4.30Average Price Target
The highest estimate is ⁦5.31⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0JVN.STU. It's not an investment recommendation.
Tesla
36
TSLA
Apple
32
AAPL
Microsoft
26
MSFT
Amazon
26
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.66B
Novavax is a competitor because it also focuses on developing vaccines using innovative technology, similar to iBio's plant-based expression system.
Moderna
MRNA
Mkt Cap88.52B
Moderna competes in the same space by developing mRNA vaccines, offering an alternative to iBio's technology for rapid vaccine development.
Pfizer
PFE
Mkt Cap173.95B
Pfizer is a major player in vaccine development and distribution, directly competing with iBio's efforts in the vaccine market.
BioNTech
BNTX
Mkt Cap22.15B
BioNTech, in partnership with Pfizer, competes in the mRNA vaccine space, offering alternatives to iBio's vaccine technologies.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson develops and markets vaccines, including its COVID-19 vaccine, competing with iBio's vaccine development efforts.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca is involved in vaccine development, including its COVID-19 vaccine, making it a competitor to iBio.
Sanofi
SNY
Mkt Cap106.24B
Sanofi is a large pharmaceutical company that competes with iBio in the vaccine market, including efforts in developing COVID-19 vaccines.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline is a competitor due to its extensive vaccine portfolio, which competes with iBio's vaccine development projects.
Dyadic International DE
DYAI
Mkt Cap15.23M
Dyadic International competes with iBio by using its proprietary C1-cell protein production platform for developing and manufacturing biopharmaceuticals, including vaccines.
Incyte
INCY
Mkt Cap24.54B
Incyte competes with iBio in the broader biopharmaceutical space, focusing on the discovery, development, and commercialization of proprietary therapeutics.

About

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
Show More
CEO
Martin Brenner
Employees
23
Country
United States
ISIN
US4510332038

Listings

STU
DE
0JV0.STU
F
DE
0JV0.F
MU
DE
0JVN.MU
MU
DE
0JV0.MU

0 Comments

Share your thoughts

FAQs

What is iBio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange iBio stocks are traded under the ticker 0JVN.STU.
When is the next iBio earnings date?▼
iBio is going to release the next earnings report on November 17, 2026.
What were iBio earnings last quarter?▼
0JVN.STU earnings for the last quarter are -0.04 EUR per share, whereas the estimation was -0.06 EUR resulting in a +27.84% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is iBio revenue for the last year?▼
iBio revenue for the last year amounts to 85,195 EUR.
What is iBio net income for the last year?▼
0JVN.STU net income for the last year is -28.51M EUR.
How many employees does iBio have?▼
As of November 7, 2026, the company has 23 employees.
In which sector is iBio located?▼
iBio operates in the Health & Wellness sector.
When did iBio complete a stock split?▼
The last stock split for iBio was on October 10, 2022 with a ratio of 1:25.
Where is iBio headquartered?▼
iBio is headquartered in NEW YORK, United States.